Why the stock of Alkem Labs is a good ‘Buy’ The stock is suitable for long-term investors, given multiple positives and reasonable valuation Alkem Laboratories, the fifth largest pharma company in India, is a dominant player in acute therapy areas with well-established brands. The company is ranked number one — market share in terms of revenue — in anti-infectives. It also has the third largest market share each in gastro-intestinal and pain and analgesics therapies. Over the years, Alkem Labs has held on to or improved its rankings in these areas. In the chronic segment too, which covers neurology, dermatology, cardiology and anti-diabetics, Alkem Labs, despite smaller presence, has managed to up its market share.